BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

(Reuters) -Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE, more than five years after both firms formed an alliance that yielded a vaccine to combat the deadly ...

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is offering about 4.55 ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults. Among 100 participants, the ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE) and BioNTech’s (BNTX) COVID-19 vaccine in young children this fall, The Guardian ...